Market Research Logo

LEO Pharma A/S - Product Pipeline Review - 2015

LEO Pharma A/S - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘LEO Pharma A/S - Product Pipeline Review - 2015’, provides an overview of the LEO Pharma A/S’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of LEO Pharma A/S’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of LEO Pharma A/S including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of LEO Pharma A/S’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the LEO Pharma A/S’s pipeline products
Reasons to buy
  • Evaluate LEO Pharma A/S’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of LEO Pharma A/S in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the LEO Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of LEO Pharma A/S and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of LEO Pharma A/S
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of LEO Pharma A/S and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


LEO Pharma A/S Snapshot
LEO Pharma A/S Overview
Key Information
Key Facts
LEO Pharma A/S - Research and Development Overview
Key Therapeutic Areas
LEO Pharma A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
LEO Pharma A/S - Pipeline Products Glance
LEO Pharma A/S - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
LEO Pharma A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
LEO Pharma A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
LEO Pharma A/S - Drug Profiles
(calcipotriene + betamethasone dipropionate)
Product Description
Mechanism of Action
R&D Progress
aprepitant
Product Description
Mechanism of Action
R&D Progress
cromolyn sodium
Product Description
Mechanism of Action
R&D Progress
ingenol mebutate
Product Description
Mechanism of Action
R&D Progress
LEO-43204
Product Description
Mechanism of Action
R&D Progress
LP-0113
Product Description
Mechanism of Action
R&D Progress
LEO-130852A
Product Description
Mechanism of Action
R&D Progress
LEO-32731
Product Description
Mechanism of Action
R&D Progress
LEO-39652
Product Description
Mechanism of Action
R&D Progress
VBY-891
Product Description
Mechanism of Action
R&D Progress
LP-0067
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize MCHR1 for Weight Loss
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Protein Kinase C for Dermatology and Cancer
Product Description
Mechanism of Action
R&D Progress
LEO Pharma A/S - Pipeline Analysis
LEO Pharma A/S - Pipeline Products by Target
LEO Pharma A/S - Pipeline Products by Route of Administration
LEO Pharma A/S - Pipeline Products by Molecule Type
LEO Pharma A/S - Pipeline Products by Mechanism of Action
LEO Pharma A/S - Recent Pipeline Updates
LEO Pharma A/S - Dormant Projects
LEO Pharma A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
(calcipotriene + hydrocortisone butyrate)
TD-1414
LEO Pharma A/S - Company Statement
LEO Pharma A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
LEO Pharma A/S, Key Information
LEO Pharma A/S, Key Facts
LEO Pharma A/S - Pipeline by Indication, 2015
LEO Pharma A/S - Pipeline by Stage of Development, 2015
LEO Pharma A/S - Monotherapy Products in Pipeline, 2015
LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2015
LEO Pharma A/S - Partnered Products in Pipeline, 2015
LEO Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2015
LEO Pharma A/S - Pre-Registration, 2015
LEO Pharma A/S - Phase II, 2015
LEO Pharma A/S - Phase I, 2015
LEO Pharma A/S - Preclinical, 2015
LEO Pharma A/S - Discovery, 2015
LEO Pharma A/S - Pipeline by Target, 2015
LEO Pharma A/S - Pipeline by Route of Administration, 2015
LEO Pharma A/S - Pipeline by Molecule Type, 2015
LEO Pharma A/S - Pipeline Products by Mechanism of Action, 2015
LEO Pharma A/S - Recent Pipeline Updates, 2015
LEO Pharma A/S - Dormant Developmental Projects,2015
LEO Pharma A/S - Discontinued Pipeline Products, 2015
LEO Pharma A/S, Other Locations
LEO Pharma A/S, Subsidiaries
List of Figures
LEO Pharma A/S - Pipeline by Top 10 Indication, 2015
LEO Pharma A/S - Pipeline by Stage of Development, 2015
LEO Pharma A/S - Monotherapy Products in Pipeline, 2015
LEO Pharma A/S - Partnered Products in Pipeline, 2015
LEO Pharma A/S - Pipeline by Top 10 Target, 2015
LEO Pharma A/S - Pipeline by Top 10 Route of Administration, 2015
LEO Pharma A/S - Pipeline by Top 10 Molecule Type, 2015
LEO Pharma A/S - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report